A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

This is a single-arm, multicenter, exploratory clinical study evaluating the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection (QL1706) and lenvatinib for perioperative treatment of resectable HCC (CNLC IIb-IIIa excluding Vp3/Vp4 or CNLC Ib-IIa with high-risk recurrence factors). Eligible subjects providing written informed consent will receive study treatment. The primary endpoint is MPR rate.

NCT Number	NCT07131501
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1, CTLA-4
Enrollment	48 participants
Start Date	2025-08-11
Primary Completion	2026-09-30 (estimated)
Study Completion	2029-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-20